Quoin Pharmaceuticals, Ltd. Sponsored ADR QNRX

Quoin Pharmaceuticals announced that the FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome (PSS), the first Fast Track for a PSS therapy, adding to the existing designation for Netherton Syndrome. The FDA previously cleared an IND for QRX003 in PSS in July 2026—the first ever for the disease. QRX003 is a topical serine protease inhibitor lotion. A Phase 2/3 trial in PSS is planned to start in 2H 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe, applying the lotion to >80% BSA for 48 weeks with a 24-week interim review. PSS has no approved treatment. Quoin targets approval in 2028. The program also notes ongoing investigation in Netherton Syndrome; the company cites Fast Track advantages. Fast Track designation and anticipated Phase 2/3 launch for a disease with no approved therapy could materially accelerate QRX003's development and regulatory pathway.

Quoin Pharmaceuticals receives FDA Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome. Rare Pediatric Disease Designation advances QRX003 toward potential priority review and market exclusivity in Peeling Skin Syndrome.

Quoin Pharmaceuticals receives FDA Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome. Rare Pediatric Disease Designation for QRX003 accelerates development timelines and strengthens Quoin's position in rare dermatology treatments.

Quoin stands to gain a second priority review voucher if its rare pediatric drug receives approval. Approval-linked voucher could provide Quoin with a monetizable asset affecting near-term valuation.

Quoin Pharmaceuticals reports positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome. Positive interim trial data for lead candidate QRX003 can materially lift investor sentiment and valuation for the company.

Quoin Pharmaceuticals announces private placement financing of up to $50.0 million. Up to $50 million private placement supplies major capital to fund operations and pipeline development.

Quoin Pharmaceuticals receives conditional FDA approval for QRX003 proposed brand name, signaling the drug nears commercialization. Conditional FDA approval advances QRX003 toward market launch and potential revenue generation for Quoin.

Quoin Pharmaceuticals released a corporate update with its second quarter 2026 financial results. Quarterly financial results and corporate updates supply data that can shift near-term investor sentiment and valuation.

Quoin Pharmaceuticals received FDA IND clearance to begin a Phase 2 study of QRX003 for Peeling Skin Syndrome. FDA clearance for Phase 2 trials marks a key regulatory milestone that can drive pipeline advancement and investor interest in QNRX.

Quoin Pharmaceuticals receives U.S. Notice of Allowance for patent covering combination treatment for Netherton Syndrome. Patent allowance strengthens Quoin's IP protection for Netherton Syndrome therapy and supports future market positioning.

Quoin Pharmaceuticals receives FDA conditional approval for QYLEKI as proposed brand name for QRX003 in Netherton Syndrome treatment. Conditional FDA brand name approval marks key regulatory progress for lead candidate QRX003, likely lifting company valuation and sentiment.

Quoin Pharmaceuticals completes setup of Japanese subsidiary to prepare commercial launch of QRX003. Japanese subsidiary advances QRX003 market entry plans but represents incremental expansion step.

Quoin Pharmaceuticals reports positive clinical updates from its ongoing compassionate use program treating pediatric Netherton Syndrome. Positive clinical data in rare disease program drives major upside for small-cap biotech stock trajectory.

Japan's MHLW granted orphan drug designation to Quoin Pharmaceuticals' QRX003 for Netherton Syndrome. Orphan designation in Japan advances QRX003 development and provides regulatory and market benefits for Netherton Syndrome.

Quoin Pharmaceuticals submits IND application for QRX003 in Peeling Skin Syndrome. IND filing marks pipeline progress for rare skin disease treatment and may lift near-term sentiment.

Quoin Pharmaceuticals (QNRX) targets completing patient recruitment for its Netherton Syndrome (NS) clinical trial by year-end 2026. Targeting NS trial recruitment completion by YE26 advances clinical pipeline progress with moderate potential to influence investor sentiment and future performance.

Quoin Pharmaceuticals reported first quarter 2026 financial results, including cash position and expenses, alongside a corporate update on pipeline progress for QRX003, QRX004, and QRX008 programs, with ongoing clinical trials and regulatory plans. Quarterly financials and pipeline updates offer moderate insight into operational health and future prospects for the biotech firm.

Quoin Pharmaceuticals announced clinical and regulatory updates for QRX009 topical rapamycin programs targeting Netherton syndrome, including positive Phase 1 results, planned Phase 2b trial, and FDA discussions on trial design. Pipeline updates on lead candidate QRX009 signal major progress in clinical development and regulatory path, potentially boosting valuation and investor confidence.

Quoin Pharmaceuticals issues correction to clinical and regulatory update for QRX009 topical rapamycin development programs. Clinical and regulatory updates on QRX009 directly affect pipeline progress and biotech investor sentiment.

Quoin Pharmaceuticals Ltd. (QNRX) is preparing to commercialize its lead asset by building a global sales infrastructure to drive international market penetration and revenue growth. Building global sales infrastructure for lead asset commercialization signals a major strategic shift toward revenue generation and market expansion.

Quoin Pharmaceuticals (QNRX) provided a corporate update and reported fourth quarter and full-year 2025 financial results. Releasing quarterly and annual financial results affects financial performance and investor sentiment.

Quoin Pharmaceuticals announced clinical and regulatory updates from a constructive Type C meeting with the U.S. FDA for QRX003 in Netherton Syndrome. Constructive FDA Type C meeting advances QRX003 regulatory path for Netherton Syndrome, significantly de-risking development and boosting investor sentiment.

Quoin Pharmaceuticals announces FDA granted Fast Track Designation to QRX003 for treating Netherton Syndrome, accelerating development and review for this rare skin disorder therapy. FDA Fast Track Designation for QRX003 speeds up development and review for Netherton Syndrome, boosting Quoin's pipeline value and investor sentiment significantly.

Quoin Pharmaceuticals (QNRX) reports several milestones: cash runway extended into 2027, Orphan Drug Designation received, and positive interim data from clinical trials. Extended cash runway to 2027 ensures financial stability, Orphan Drug Designation provides regulatory advantages, and positive interim data advances key pipeline programs.

Quoin Pharmaceuticals (QNRX) advances lead asset QRX003 with extensive distribution network in place to support commercialization prospects. Advancing QRX003 with ready distribution network signals major progress toward commercialization, potentially altering QNRX's trajectory and investor sentiment.

Quoin Pharmaceuticals has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for orphan drug designation for its product QRX003, aimed at treating Netherton Syndrome. This designation could facilitate the development and commercialization of QRX003 in Japan, providing potential benefits for patients suffering from this rare genetic condition. The orphan drug designation could significantly enhance QRX003's market potential and Quoin's strategic positioning in the rare disease sector.

Quoin Pharmaceuticals, Ltd. Insider increased their holding by an astonishing 1,515,200% over the past year, indicating a strong personal investment in the company. This dramatic rise in ownership suggests heightened confidence in Quoin's future prospects and may influence market perceptions positively. A significant increase in insider ownership typically signals strong confidence in the company's future, potentially impacting investor sentiment and market performance.

Quoin Pharmaceuticals has submitted a Breakthrough Medicine Designation application in Saudi Arabia for its treatment QRX003, aimed at addressing Netherton Syndrome. This designation could expedite the development and review process for the drug, potentially enhancing its market entry and availability for patients suffering from this rare genetic condition. The Breakthrough Medicine Designation could significantly accelerate the development and commercialization of QRX003, impacting Quoin's future performance.

Quoin Pharmaceuticals, Ltd. has achieved several significant milestones, including extending its cash runway into 2027 and receiving orphan drug designation for its lead product candidate. Positive interim data from ongoing clinical trials further supports the company's growth prospects. The extension of the cash runway and receipt of orphan drug designation are likely to significantly impact future performance and investor sentiment.

Quoin Pharmaceuticals has successfully achieved target loadings of topical rapamycin using two proprietary delivery technologies. This milestone is expected to enhance the efficacy of their product offerings and potentially improve patient outcomes in dermatological applications. The company aims to leverage these advancements to strengthen its position in the pharmaceutical market. Achieving target loadings for proprietary delivery technologies is a significant advancement that could enhance product efficacy and market positioning.